Menu
ETF
Annual · values202520242023202220212020201920182017201620152014
Operating Cash Flow-5.33 M USD-12.53 M USD-8.78 M USD-5.25 M USD-1.83 M USD-657299 USD-495798 USD-512806 USD-543520 USD-314182 USD-867644 USD-538595 USD
Depreciation & Amortization332070 USD223527 USD149147 USD25163 USD12741 USD14066 USD13774 USD49361 USD6629 USD60731 USD4251 USD0 USD
Stock-Based Compensation271930 USD277252 USD755215 USD520271 USD702300 USD116500 USD1.26 M USD
Capital Expenditures174491 USD1.66 M USD82251 USD193982 USD0 USD1191 USD860 USD18850 USD3718 USD3439 USD4793 USD0 USD
Cash Flow from Investing-836306 USD-2.32 M USD-656150 USD-14.62 M USD0 USD-1191 USD-15276 USD-13908 USD-84008 USD-3439 USD-623603 USD0 USD
Cash Flow from Financing4.75 M USD9.29 M USD3.43 M USD39.47 M USD2.90 M USD1.61 M USD442255 USD527640 USD670705 USD324622 USD1.40 M USD650778 USD
Dividends Paid
Stock Buybacks0 USD3.14 M USD541143 USD
Free Cash Flow-5.51 M USD-14.19 M USD-8.86 M USD-5.44 M USD-1.83 M USD-658490 USD-496658 USD-531656 USD-547238 USD-317621 USD-872437 USD-538595 USD

Sunshine Biopharma Inc. is a pharmaceutical company focused on the research, development, commercialization, and distribution of medicines across oncology, antivirals, and other therapeutic areas. Through its commercial operations, the company markets generic prescription drugs in Canada, including treatments used for cholesterol management, bacterial infections, and nausea relief, primarily through its Nora Pharma subsidiary. Sunshine Biopharma also works on biosimilar products and preclinical drug candidates aimed at cancer and viral diseases, supporting a portfolio that spans approved medicines and experimental programs. In addition to prescription pharmaceuticals, the company is involved in science-based nutritional supplements, giving it a broader presence in the healthcare market. Sunshine Biopharma Inc. plays a role in supplying affordable therapeutic options and advancing drug development in regulated pharmaceutical markets.